Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 13Leukemia, Biphenotypic, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Accelerated Phase 1Down Syndrome 1Blast Crisis 1

Interventions

ponatinib 4Methotrexate 4Cytarabine 4Cyclophosphamide 4merphos 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3venetoclax 2fludarabine phosphate 2Tacrolimus 2Idarubicin 2Etoposide 2Cyclosporine 2Cladribine 2Busulfan 2prednylidene 1nilotinib 1midostaurin 1gilteritinib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1bosutinib 1blinatumomab 1auricularum 1asciminib 1Vincristine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 90 days × Clear all
NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡